Funder
U.S. Department of Health & Human Services | National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference29 articles.
1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.
2. Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GTT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263:160–72.
3. Guang MHZ, McCann A, Bianchi G, Zhang L, Dowling P, Bazou D, et al. Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’. Leuk Lymphoma. 2018;59:542–61.
4. Raedler LA. Farydak (Panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma. Am Health Drug Benefits. 2016;9:84–7.
5. Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol. 2016;104:300–9.
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献